Silicon Biosystems SpA, a provider of specialized molecular and cell biology technology, has formed a US subsidiary operation, Silicon Biosystems Inc, to be headquartered in San Diego. The newly formed business will focus on commercial operations and the development of the North American research and clinical diagnostics markets for the company’s DEPArray™ technology platform.
“The formation of our own commercial operation in the US represents a significant step forward for our business,” said Giuseppe Giorgini, CEO of Silicon Biosystems SpA. “Our DEPArray platform will allow clinicians and researchers working to advance personalized medicine in areas such as clinical oncology to identify new biomarkers and improve patient treatment based on genetic information they have previously not had access to. We are excited to begin commercial discussions with thought leaders in the US.”
The company’s DEPArray technology exploits microelectronics and the principles of dielectrophoresis to isolate and manipulate cells in a suspension matrix. The approach, patented by Silicon Biosystems, offers the unique possibility of controlling individual cells and micro-particles inside a disposable cartridge. The DepArray platform makes it possible to find, sort, select and separate individual cells for further analysis or culturing.
Source: Silicon Biosystems SpA
